the benefit of using the generic name in this case is the historical scientific data all points back to Bisantrene. Zantrene does not, so I think smart move!
Ann: Letter to Shareholders, page-55
-
- There are more pages in this discussion • 41 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.59 |
Change
0.145(10.1%) |
Mkt cap ! $259.8M | |||
| Open | High | Low | Value | Volume |
| $1.46 | $1.60 | $1.46 | $238.1K | 156.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4605 | $1.59 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.61 | 4288 | 4 |
View Market Depth
| Last trade - 15.57pm 12/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |